Why Published Expertise Is Becoming a Discovery Advantage

Claims in this piece are observable and methodological — no client or benchmark data used.

Two contract manufacturers can hold the same depth of genuine expertise: the same years of sterile fill-finish experience, the same command of complex technology transfer, the same regulatory track record. One has written almost none of it down anywhere a stranger can find. The other has made that expertise visible — capability explained clearly, process described, the specifics of what it does and for whom stated plainly in public.

To the company’s own team, the two look equally expert. To an overseas buyer researching partners — and increasingly to an AI assistant helping them — they do not look equal at all. The second is discoverable and credible before the first conversation. The first is, in practical terms, invisible until someone already knows to look for it.

That gap is the subject of this article. The point is not that expertise has stopped mattering — it matters more than ever during formal evaluation. The point is narrower and, for a specialist manufacturer, more uncomfortable: expertise that is never made public cannot do commercial work at the discovery stage, because no outsider can establish that it exists.

Expertise and the evidence of expertise are not the same thing

There is a quiet assumption in a lot of pharmaceutical business development: that genuine capability will, eventually, be recognised. That good work speaks for itself. In a relationship-driven market, over a long enough horizon, there was truth to it — reputation travelled through people who already knew you.

But the discovery stage has changed, in a way explored across Emerivo’s earlier research on why some manufacturers are shortlisted before the first sales call. A growing part of a buyer’s early research now happens before you know they exist, using only what is publicly discoverable. At that stage, a stranger — or a system working on their behalf — cannot access your expertise. It can only access the evidence of your expertise: what you have made establishable in public.

Those two things diverge more often than manufacturers expect. A company can hold genuine, differentiated depth in a narrow, high-value capability and have almost nothing public that lets an outsider confirm it. The capability is real. The evidence is thin. And at the discovery stage, the evidence is all there is.

Why publishing expertise is a discovery advantage, not a marketing exercise

It is tempting to file “publish more content” under marketing, and to treat it as optional polish. That framing misses what is actually happening.

When a manufacturer publishes genuine expertise — a clear explanation of a specialised capability, the considerations in a particular kind of technology transfer, what distinguishes its approach in a specific therapeutic or technical area — it does something specific and commercial: it converts private competence into public, establishable evidence. That evidence is what a buyer’s early research runs on, and what an AI assistant can interpret and represent when a buyer asks a relevant question.

This is not about volume, and it is not about sounding impressive. A hundred pages of generic “committed to quality and innovation” language publishes no expertise at all — it gives an outsider nothing specific to establish. A single, genuinely expert explanation of how the company approaches, say, lyophilised injectable manufacturing for regulated markets publishes real evidence. The distinction is substance, not quantity.

The signature idea is this: unpublished expertise is, at the discovery stage, invisible expertise. Knowledge becomes a discovery advantage only when it is made establishable by someone who has never met you.

What “published expertise” actually means for a manufacturer

It does not mean turning your specialists into content creators, or chasing an audience. For a CDMO, published expertise is narrower and more practical. It is making the genuine substance of your capability legible in public:

• Specific capability explained, not just listed — not “sterile manufacturing” as a menu item, but a real explanation of what you do, at what scale, under which conditions, for which markets.
• The reasoning behind the capability — the considerations, trade-offs, and approach that show genuine depth rather than asserting it. This is what distinguishes demonstrated expertise from a claim.
• The specialised knowledge that differentiates you — where you have real depth (HPAPI containment, complex technology transfer, a particular therapeutic area), made visible and specific enough that an outsider can connect it to a buyer’s need.
• Accurate, current, and consistent — expertise published once and left to drift out of date becomes misleading evidence. Published expertise is only an asset while it remains true.

None of this requires inventing capability or overclaiming. That would fail the only test that matters at evaluation — verification. It requires making real expertise findable and establishable, which is a different and more honest exercise than marketing.

Published expertise works across audiences at once

Published expertise has a property ordinary marketing does not: the same substance serves several audiences simultaneously. One clear, specific explanation of a capability serves the human evaluator reading your pages, the AI assistant a buyer uses to research the field, and the coherence of your wider public record — because a substantive, accurate account of what you do is exactly what makes the rest of your presence hang together. The reason this matters for AI-assisted discovery specifically is covered in When AI Recommends a CDMO, What Is It Actually Evaluating?: an assistant builds its account of you from what it can establish, and published expertise is the richest, most specific evidence you can give it to work from. Unlike a claim, it also rests on real capability, so it holds up when a buyer moves from research to verification.

A demonstration you can run

You can observe the gap between your expertise and its public evidence directly. Take one capability where you have genuine, differentiated depth. Then ask ChatGPT, Gemini, Perplexity, Claude and Copilot a question a buyer in that area might ask — for example:

Which CDMOs demonstrate real depth in lyophilised injectable manufacturing for regulated markets, and what distinguishes them?

Read the answers not for whether you appear, but for whether any assistant can articulate the specific expertise you know you hold. Can it explain what you do at the level of depth that is actually true? Or does it fall back on generic description — or omit the capability entirely? Where an assistant cannot express expertise you genuinely have, that is usually not a failure of the model. It is a sign that the expertise has not been published as establishable evidence. This is a reproducible observation, not a benchmark or a ranking — results vary by platform, prompt, and time.

The practical takeaway

Expertise still wins business — at the table, under evaluation, where it always has. What has changed is what happens before the table. A buyer’s early research, increasingly AI-assisted, runs on public evidence, and a manufacturer’s genuine expertise is only part of that evidence to the extent it has been made establishable. The specialist that publishes its real depth becomes discoverable and credible before the first conversation. The equally-expert specialist that publishes nothing competes only once someone already knows to look — which, at the discovery stage, is increasingly no one.

The work is not to manufacture expertise or to publish more for its own sake. It is to make the genuine expertise you already hold legible to a stranger, and to keep it accurate over time. That is what turns competence into a discovery advantage.

Emerivo helps pharmaceutical manufacturing and research organisations — TPMs, CMOs, CDMOs and CROs — understand how AI assistants find, interpret and represent them during supplier discovery. The AI Discovery Audit™ tests what AI assistants can currently establish about an organisation against realistic buyer questions — diagnostic, not a promise of rankings or recommendations. For the wider argument, see Why Some Pharmaceutical Manufacturers Are Shortlisted Before the First Sales Call and When AI Recommends a CDMO, What Is It Actually Evaluating?.

Frequently asked questions